Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

Zelicapavir (EDP-938) study results in HCST study

This pt population continued to be very cautious post covid w masking etc making enrollment difficult so the study was terminated early

there were 6 efficacy evaluable patients, 3 tx and 3 pbo, with detectable RSV by PCR.
Mean reduction in VL was -7.072 log in the tx arm versus -2.221 in the pbo arm
clinical endpoint of patients progressing to respiratory failure/mechanical ventilation was zero in both arms, not surprising w such low enrollment
While N is very low this is still a very dramatic difference in VL reduction in a real world setting and bodes well IMO for the outcome of the peds study where change in VL is a primary outcome

https://clinicaltrials.gov/study/NCT04633187?term=edp-938&rank=9&tab=results